Glenmark Pharmaceuticals

Glenmark Pharmaceuticals's reported carbon emissions

In 2024, Glenmark Pharmaceuticals reported total greenhouse gas emissions of approximately 171,146,000 kg CO2e, comprising 15,455,000 kg CO2e from Scope 1, 69,632,000 kg CO2e from Scope 2, and 171,146,000 kg CO2e from Scope 3 emissions. This reflects a slight decrease in emissions compared to 2023, where total emissions were approximately 175,069,000 kg CO2e, with Scope 1 at 12,703,000 kg CO2e, Scope 2 at 64,812,000 kg CO2e, and Scope 3 at 175,069,000 kg CO2e. Glenmark Pharmaceuticals has set ambitious climate commitments, aiming for carbon neutrality by 2030 for its Scope 1 and Scope 2 emissions through targeted decarbonisation initiatives. Additionally, the company has committed to reducing its absolute Scope 1 and 2 GHG emissions by 35% by FY2035 from a FY2021 baseline, while also targeting a 28% reduction in Scope 3 emissions per ton of pharmaceutical products within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are classified as consistent with keeping global warming well below 2°C. Glenmark's proactive approach to climate action underscores its commitment to sustainability within the pharmaceutical sector, reflecting a growing trend among companies to address their environmental impact comprehensively.